Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (NASDAQ: TWST) has entered into a royalty purchase agreement with XOMA Royalty (NASDAQ: XOMA). Under the agreement, XOMA Royalty will provide Twist with an upfront payment of $15 million in exchange for the right to receive half of the future potential milestone and royalty payments from Twist's existing antibody discovery and biopharma services collaborations.
Twist will retain all upfront, service, and other revenue from these collaborations, as well as full rights to future biopharma collaborations with milestone and royalty terms. The agreement does not apply to synbio, NGS, or data storage revenue. This deal aims to provide Twist with immediate capital to support continued innovation and profitable growth across the company.
Twist Bioscience (NASDAQ: TWST) has appointed Mike Fero, Ph.D., as Chief Information Officer. Dr. Fero brings over 30 years of experience in startups, commercial software development, biology and physics research, and deep-tech businesses. His background includes building scalable enterprise software platforms and understanding systems biology and artificial intelligence. Dr. Fero was previously a Twist customer, giving him unique insights into the company's mission.
Before joining Twist, Dr. Fero co-founded and served as CEO of TeselaGen Biotechnology for a decade, developing an enterprise software platform for DNA design and management. He has also held positions at Stanford University, Neomorphic, HyperParallel, and MIT. Dr. Fero holds a Ph.D. in Physics and a B.A. in Math and Physics from UC Irvine.
Twist Bioscience (NASDAQ: TWST) has achieved LEED certification for its Wilsonville, OR facility, demonstrating its commitment to sustainability in operations and maintenance. The certification, awarded by the U.S. Green Building Council, recognizes the facility's adherence to LEED v4.1 Operations + Maintenance standards.
CEO Emily M. Leproust emphasized that this achievement aligns with Twist's mission to improve health and sustainability. The company previously quantified the carbon footprint of gene production using their platform, showing significant environmental benefits compared to traditional methods. This LEED certification further solidifies Twist's commitment to providing customers with DNA produced in a sustainable facility using fewer chemical reagents.
Twist Bioscience (NASDAQ: TWST) has released its 2024 corporate responsibility report, highlighting its commitment to sustainability, social responsibility, and ethics. The company's silicon-based DNA manufacturing platform offers a more sustainable alternative to legacy methods, using 99.8% less reagents than 96-well plate approaches.
Key points:
- Twist's oligo manufacturing process for NGS target enrichment panels emits significantly less CO2 compared to industry standards
- The company disclosed its Scope 1 and Scope 2 emissions for the first time
- Twist prioritizes biosecurity, cybersecurity, and data protection
- The company fosters a diverse workforce, with 56% of U.S. employees identifying as individuals of color
- Twist invested over $220,000 in employee learning and development in fiscal 2023
Twist Bioscience (NASDAQ: TWST), a leading synthetic DNA provider, has announced its participation in the Baird Global Healthcare Conference 2024. Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present on Tuesday, September 10 at 2:35 p.m. Eastern Time in New York City.
The presentation will be webcast live and accessible through the company's investor relations website. A replay will be available for 30 days following the event. This conference appearance provides an opportunity for Twist Bioscience to showcase its silicon-based DNA synthesis platform and engage with healthcare industry professionals and investors.
Twist Bioscience (NASDAQ: TWST) has expanded its DNA synthesis offering with the launch of Gene Fragments ranging from 1.8kb to 5.0kb in length. This industry-leading product is available through Twist's ecommerce platform, offering the same speed, quality, and affordability as shorter fragments. Key features include:
- Turnaround time starting at two business days
- Low error rate of 1:7,500 base pairs
- Customizable with no order limit
- Universally compatible with various downstream cloning methods
The expanded offering aims to serve researchers at all stages, from Makers to Buyers, and is particularly beneficial for RNA therapeutic screening applications. Twist's CEO, Emily M. Leproust, Ph.D., emphasized the company's goal to push the boundaries of DNA synthesis and meet diverse customer needs.
Twist Bioscience (NASDAQ: TWST) has announced the granting of 94,200 restricted stock units (RSUs) to 30 newly hired employees as an inducement for their employment. This action was taken under Twist's Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, with 25% vesting on the one-year anniversary of the employee's start date and 1/16 vesting quarterly thereafter, contingent on continued employment. This plan is exclusively used for granting equity awards to new hires or those returning after a significant break in employment.
Twist Bioscience (Nasdaq: TWST) and bitBiome have announced a strategic collaboration, launching a joint Transaminase Enzyme Screening Kit. This kit contains 48 diverse transaminase enzymes for in-house screening and evaluation. The collaboration combines Twist's high-capacity DNA synthesis technology with bitBiome's proprietary database of over two billion microbe sequences.
The kit aims to provide labs and pharmaceutical companies with improved enzymes for biocatalysis, particularly for synthesizing active pharmaceutical ingredients (APIs). Transaminases are important in creating chiral amines, valuable building blocks for the pharmaceutical industry, offering a potential 'green alternative' to conventional synthesis methods.
This partnership leverages bitBiome's diverse sequence database and Twist's large-scale DNA synthesis capabilities to create innovative solutions for the biomanufacturing industry.
Twist Bioscience (NASDAQ: TWST) reported strong fiscal Q3 2024 results, with record revenue of $81.5 million, up 28% year-over-year. The company saw significant improvements in gross margin, reaching 43.3%, a 900 basis point increase from the previous year. Twist raised its FY 2024 revenue guidance to $310-$311 million and expects gross margin to be at the high end of the range at approximately 42%.
Key highlights include:
- SynBio revenue grew to $33.0 million
- NGS revenue increased to $43.4 million
- Biopharma revenue reached $5.1 million
- Shipped products to approximately 2,300 customers
- Launched new products including Multiplexed Gene Fragments and Express Antibodies
Despite the strong revenue growth, Twist reported a net loss of $85.6 million for the quarter, including a $45 million impairment related to Biopharma assets.
Twist Bioscience (NASDAQ: TWST) announced the first patient dosing in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405, a fully human IgG1 antibody discovered using Twist's synthetic antibody phage display libraries. The study aims to evaluate the pharmacodynamic activity of PBA-0405 in solid tumors, including head and neck squamous cell carcinoma, certain soft-tissue sarcomas, and triple-negative breast cancer.
PBA-0405 targets ROR1, a tumor-associated antigen, and is designed to make tumors visible to the immune system and induce an immune response. This marks the first antibody identified using Twist Biopharma Solutions' Library of Libraries to be tested in patients, validating the potential of their synthetic antibody libraries for discovering novel drug candidates for hard-to-treat cancers.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
